Theravance Biopharma Inc (TBPH)Healthcare | Biotechnology | South San Francisco, United States |
USD
|
Hot Take ↕ | Oct. 10, 2026, 1:41 p.m. UTC
The immediate outlook is flat due to a complete lack of price history and statistical data, leaving no momentum edge to exploit. While the company boasts a fortress balance sheet with massive liquidity relative to debt and impressive profitability margins, the business is currently contracting with a 21% drop in revenue growth, which prevents any upgrade on the long-term front despite the attractive valuation multiples. Furthermore, there is no dividend income to offset the stagnation, making this a speculative hold rather than a compelling investment vehicle at this time. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 13.313 |
| Revenue per Share | 2.042 |
| Market Cap | 884,176,384 |
| Trailing P/E | 16.38 |
| Forward P/E | 13.36 |
| Beta | 0.25 |
| Profit Margins | 51.58% |
| Website | https://www.theravance.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.18181813 |
| Address1 | 901 Gateway Boulevard |
| All Time High | 43.44 |
| All Time Low | 6.1 |
| Ask | 21.64 |
| Ask Size | 200 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 1,899,764 |
| Average Volume | 763,084 |
| Average Volume10Days | 1,899,764 |
| Beta | 0.245 |
| Bid | 12.14 |
| Bid Size | 200 |
| Board Risk | 1 |
| Book Value | 5.583 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Currency | USD |
| Current Price | 17.03 |
| Current Ratio | 13.543 |
| Date Short Interest | 1,789,430,400 |
| Day High | 17.07 |
| Day Low | 17.02 |
| Debt To Equity | 13.313 |
| Ebitda | 11,102,000 |
| Ebitda Margins | 0.106429994 |
| Enterprise To Ebitda | 48.197 |
| Enterprise To Revenue | 5.13 |
| Enterprise Value | 535,088,384 |
| Exchange | NGM |
| Exchange Timezone Name | UTC |
| Fifty Day Average | 16.9694 |
| Fifty Two Week High | 21.03 |
| Fifty Two Week Low | 13.08 |
| Financial Currency | USD |
| First Trade Date Epoch Utc | 1,784,295,000 |
| Float Shares | 25,870,077 |
| Forward Eps | 1.275 |
| Forward P E | 13.356864 |
| Free Cashflow | 5,300,875 |
| Full Time Employees | 90 |
| Fullday Change | 0.0 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 17.03 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,788,220,800 |
| Gross Margins | 0.75061995 |
| Gross Profits | 78,298,000 |
| Held Percent Insiders | 0.04607 |
| Held Percent Institutions | 0.94707 |
| Implied Shares Outstanding | 51,918,754 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California. As of September 23, 2026, Theravance Biopharma, Inc. operates as a subsidiary of Zymeworks Inc. |
| Long Name | Theravance Biopharma Inc |
| Market Cap | 884,176,384 |
| Max Age | 86,400 |
| Message Board Id | finmb_240999442 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 53,808,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 884,176,380 |
| Number Of Analyst Opinions | 3 |
| Open | 17.06 |
| Operating Cashflow | 53,742,000 |
| Operating Margins | 0.0889 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Phone | 650 808 6000 |
| Previous Close | 17.03 |
| Price Hint | 2 |
| Price To Book | 3.0503314 |
| Price To Sales Trailing12 Months | 8.476349 |
| Profit Margins | 0.51584 |
| Quick Ratio | 13.263 |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 3.0 |
| Regular Market Day High | 17.07 |
| Regular Market Day Low | 17.02 |
| Regular Market Open | 17.06 |
| Regular Market Previous Close | 17.03 |
| Regular Market Volume | 10,016,289 |
| Return On Assets | 0.0133299995 |
| Return On Equity | 0.20914 |
| Revenue Growth | -0.209 |
| Revenue Per Share | 2.042 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 51,918,754 |
| Shares Percent Shares Out | 0.0325 |
| Shares Short | 1,686,673 |
| Shares Short Previous Month Date | 1,786,665,600 |
| Shares Short Prior Month | 1,714,947 |
| Short Name | Theravance Biopharma, Inc. |
| Short Percent Of Float | 0.051799998 |
| Short Ratio | 4.54 |
| State | CA |
| Symbol | TBPH |
| Target High Price | 19.0 |
| Target Low Price | 17.0 |
| Target Mean Price | 17.66667 |
| Target Median Price | 17.0 |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 387,656,992 |
| Total Cash Per Share | 7.467 |
| Total Debt | 38,569,000 |
| Total Revenue | 104,311,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 1.04 |
| Trailing P E | 16.375002 |
| Trailing Peg Ratio | None |
| Two Hundred Day Average | 17.158976 |
| Underlying Symbol | TBPH |
| Uuid | f44e86c3-1b7b-3131-b6a5-9cdef50528ba |
| Volume | 10,016,289 |
| Website | https://www.theravance.com |
| Zip | 94,080 |